Showing posts with label infectious disease. Show all posts
Showing posts with label infectious disease. Show all posts

Thursday, February 5, 2015

Populations, individuals and imprecise disease prediction

As Michael Gerson writes in the Washington Post, "Preventable infectious disease is making its return to the developed world, this time by invitation." When anti-vaxxers were few, and they chose not to expose their kids to what they consider toxins, their kids benefited from the herd immunity that resulted from most parents choosing to have their kids vaccinated (or, as Gerson puts it, anti-vaxxers chose to be free-riders).  They could claim there were no costs to their action (or non-action), because as long as they were a small minority, there weren't.

But unlike many complex non-infectious diseases, infectious diseases are very predictable. Once the proportion of a population that is immunized falls below a certain threshold, as determined by the rigorous and empirically tested mathematics of infectious disease, the kids of anti-vaxxers are then sitting ducks for disease once they are exposed, and the disease is then likely to spread even to the immunized population because no vaccine is 100% effective.  And this is happening in the US now with measles.  Anti-vaxxers convinced enough of their neighbors not to vaccinate that they can no longer claim no cost, only benefits to their beliefs.

From Mother Jones, 2014

In theory, herd immunity protects a population from measles when at least 90-95% of the population is vaccinated, so the above map would suggest that even in Oregon, with a rate of non medical immunization exemption over 6%, the disease would be unable to gain a foothold.  But, infectious disease researcher Marcel Salathé who is here at Penn State nicely describes herd immunity here, and suggests that something closer to 100% coverage would actually be required to protect against measles because of pockets of lower vaccination rates, and non-random mixing of the population and so forth.

The science on the safety and efficacy of vaccination is well-established. Vaccines can have side-effects, but it's pretty clear the list doesn't include autism.  (Has anyone estimated the prevalence of autism in anti-vaxxer communities yet?  If they were right that the MMR vaccine causes autism, the rate should be a lot lower in unvaccinated kids by now, no?)  The freedom of choice issue, of whether the state has a right to require individuals to be vaccinated, is a live one, and any conscientious objector to the right of society to make decisions for individuals has to be struggling with this one, given the societal consequences.  This is distinctly not the same as an individual's freedom to decide whether to smoke or to drink jumbo soft drinks because in the case of vaccines, what's good for society is also good for individuals, and vice versa.

Measles virus; Wikipedia (Cynthia S Goldsmith Content Provider, CDC) 

But that's not what interests me particularly here.  What interests me is the interplay between population and individual disease dynamics.  Infectious disease dynamics depend on the proportion of susceptible individuals in the population; too few and the disease dies out, enough and the disease sticks around, cyclically infecting people as, say, the flu, or endemic, as, e.g., venereal diseases.  So, in a very real sense infectious disease happens to a group, in a group, and because of a group, at the same time it's happening to individuals in that group.  But chronic non-infectious diseases (CNIDs) don't work that way.  Chronic non-infectious diseases happen to individuals only, irrespective of what's happening to anyone else in the population (though, see below).

But, what we know about and predict for individuals depends on what we know (or think we know) about a CNID in a population.  Epidemiologists collect data in a group on what may be relevant risk factors, and then statistically estimate their importance and impact. Observations on a single individual don't have the power to allow epidemiologists to determine which risk factors are likely to be important.  That requires repeated observations, on many people.

So, calculations of how likely you are to have a heart attack given your age, body mass index, cholesterol levels and so on are based on population associations between such factors and actual heart attacks.  These are based on past observed experience in many individuals.  As we've written many times before, it's not really clear what 'risk' represents, other than the observed proportion of a population with apparent past exposure to tested risk factors who went on to develop a disease.  But, a lot of people with the same risk factors didn't develop disease, or have a heart attack or whatever, and a lot of people without those risk factors did.  So, risk estimates are population-based statistics that may or may not apply to you -- or anyone individually, really.  They are collective data, and clearly don't explain all risk, or allow precise prediction.

Now, social epidemiologists would say that chronic diseases can be as much a result of population factors as infectious diseases are.  Smoking, obesity, drinking, stress-related diseases are correlated with social class, so in a very real sense, population dynamics can affect risk of CNIDs as well.  So, if we want to explain CNIDs by distal rather than proximal risk factors, population dynamics become important, as with infectious diseases.  But they are still population-level factors -- not every low-income individual is obese or has high blood pressure, and not every overweight individual is poor.  But, everyone with measles has been infected by the measles virus.

The population issue, I think, goes a long way toward explaining why it's so hard to predict chronic disease, genetic or otherwise.  We're forced to infer group statistics to individuals, and that's never going to be precise.

Monday, December 8, 2014

Genetics -- fiddling while Rome burns

Stories about the growing threat of antibiotic resistance generally include alarming predictions about the coming post-antibiotic era, about how even simple medical procedures that are now safe will become dangerous once we lose the ability to fight infections, and indeed simple infections will once again become life-threatening, as they might have been for most of human history.  We in the rich world can still imagine that this future might be avoidable, as we've still got useful drugs for many of our microbial illnesses -- plus, we're pretty good at being delusional (see climate change).

But that ominous future is already here for much of the world.  A reader sent us a link to a heart-wrenching story in the Dec 3 New York Times; "'Superbugs'" Kill India's Babies and Pose an Overseas Threat", Gardiner Harris.  Lack of widespread public health measures including sanitation are largely responsible for high infant mortality rates in poor nations.  Infectious diseases that would be avoidable or easily treated in rich countries are lethal in countries where the health care infrastructure is weak.  Antibiotic resistance is more widespread in these same countries, exacerbating the health care challenge.

The infant mortality rate (IMR) in India was 41/1000 live births in 2013, or 4%! -- by contrast, the lowest rates in the world in 2013, in Israel and Ireland and several other nations, were 3/1000, or 0.3%.  The IMR hasn't been as high in the United States as it is now in India since the beginning of the antibiotic age.  But India may never see the kind of decrease in infant mortality that the US experienced beginning in the 1940's, and it looks as though growing antibiotic resistance will be a major reason.

Infant, post-neonatal and neonatal morality rates, United States, 1940-2006; deaths per 1000 live births; CDC

In India, Harris reports, many infants are already dying of infections that are resistant to multiple antibiotics.  And, "a significant share of the bacteria present in India— in its water, sewage, animals, soil and even its mothers — are immune to nearly all antibiotics."  And those bacteria are quickly traveling around the world.

For many reasons, bacterial infections spread quickly in India; people defecate outdoors, sewage is untreated, drinking water can be contaminated, hospitals can be a source, even as they are in the West, and so on.  The most frequent bacterial infections in infants are from bacteria found in human waste.  And to compound the problem, antibiotics are available over-the-counter, in recent years women have been encouraged to give birth in hospitals, often in unsanitary conditions, and, Harris reports, infants have often been given antibiotic injections preventatively, all of which adds to growing resistance.
“Reducing newborn deaths in India is one of the most important public health priorities in the world, and this will require treating an increasing number of neonates who have sepsis and pneumonia,” said Dr. Vinod Paul, chief of pediatrics at the All India Institute of Medical Sciences and the leader of the study. “But if resistant infections keep growing, that progress could slow, stop or even reverse itself. And that would be a disaster for not only India but the entire world.”
In addition, antibiotic resistance is linked to widespread use in animal husbandry; the increased industrialization of meat production in India, with accompanying antibiotic use, may be adding to the problem there.

None of this is a surprise.  Just as the increase in 'super weeds' as a result of the widespread use of plants genetically modified to resist herbicides, which are then liberally sprayed on fields, was completely predictable.  Like the herbicide Round-Up, antibiotics are a strong selective force that encourage resistance.

But this is much more than a science problem.  It's a social, and an economic and a moral problem. Antibiotic resistance is developing much more quickly in poor countries, because of lack of public health infrastructure, and more infectious disease in general.  Preventing it takes resources, and it hasn't been a very glamorous claim on resources for high-flying research investigators who are driven by our society's worship of high technology.  But as we've written before, spending billions of dollars on things like genetics -- or, say, flights to Mars -- may well turn out to be fiddling while Rome burns.

Thursday, November 13, 2014

Evolution of malaria resistance: 70 years on...and on....and on

It was about 70 years ago that the complex problem of anemia, malaria, and genetic interactions, with their relation to hemoglobin was first beginning to be understood.  Sickle cell anemia and its association with a globin gene variant, and similar associations between malarial susceptibility and other genes (such as G6PD and Duffy and other globin gene mutations) were also rapidly identified in roughly the same decades.  The findings were showing that in areas of the world with long-endemic malaria, various gene mutations seemed to be at high frequency as if they protected against malaria.  I was never involved in this directly, but I studied under Frank Livingstone and James V Neel at Michigan, two of the leaders in understanding the evolution of the protective mechanisms.

For decades we have had direct clinical evidence, mainly in Africa, but also in Sardinia, and then later in other places including southeast Asia, that at least some of the putatively protective mutations in the alpha and beta globin, and other genes did in fact protect against malaria, but that they had side effects such as various forms of anemia or other problems.  Even then most of the evidence was circumstantial and based on geographic correlations.

The idea of a balanced polymorphism was suggested in regard to these variants.  If you had two 'malaria-protective' alleles at the gene (one in each copy of the gene that you have), you were vulnerable to anemia, but if you had two 'normal' alleles you were susceptible to malaria; however, having one of each (a heterozygote genotype) you had some protection against both malaria and anemia.  Evolution favored keeping both variants in the population, because selection worked against both homozygotes.

Plasmodium falciparum lifestyle; Wikipedia

Far beyond malaria: Relationship to fundamental evolutionary questions
The idea of balanced polymorphisms played into a major theoretical argument among evolutionary biologists at the time, and sickle cell anemia became a central case in point, and a stereotypical classroom example. But the broader question was quite central to evolutionary theory.  Balancing selection was, for many biologists who held a strongly selectionist version of Darwinism, the explanation for why there was so much apparently standing genetic variation in humans, but  generally in all, species.

The theory had been that harmful mutations (the majority) are quickly purged, so the finding that there was widespread variation (polymorphism) in nature at gene after gene, the result of the type of genotyping possible then (based on protein variation), demanded explanation; balanced polymorphism provided it.  This was countered by a largely new, opposing view called 'non-Darwinian' evolution, or the 'neutral' theory; it held that much or even most genetic variation had no effect on reproductive success, and the frequency of such variants changed over time by chance alone, that is, experience 'genetic drift'.  This seemed heretically anti-Darwinian, though that was a wrong reaction and only the most recalcitrant or rabid Darwinist today denies that much of observed genomic variation evolves basically neutrally.  But many saw the frequency of variants associated with what were seen as serious recessive diseases, like PKU and Cystic Fibrosis (and others) as the result of balancing selection.

In support of the selectionist view, many variants have been found in the globin and other genes for which the frequency of one or more alleles is correlated geographically with the presence (today, at least) of endemic malaria.  But there are lots of variants that might be correlated with other things geographic because the latter are themselves often correlated with population history.  Thus, the correlations are often empirical but not clearly causal.  Indeed, not many variants have been clearly shown experimentally or clinically actually to be functionally related to malaria resistance.

In this light it is interesting to see a rather large-scale attempt at testing whether putative malaria-associated variants really are protective. The paper ("Reappraisal of known malaria resistance loci in a large multi center study") by a large consortium of authors is in the November 2014 Nature Genetics; it is paywalled so if you don't have direct access but would like to read it, I'd be happy to email a pdf.

These authors compiled large data sets from different areas of the world which have endemic malaria caused by the specific falciparum subtype of parasite, and compared the frequency of the many candidate gene variants in sufferers of severe malaria to a large set of unaffected controls (of course some of them may later become affected).

A long time coming...and the clock still ticking
Even now, 70 years after the first ideas were suggested, we still have scant direct clinical data showing protection at a mechanistic level, so the results of this paper are still statistical.  But they are at least from a reasonably designed and specific study.  The authors found positive statistical association for some of the most clear-cut classical risk alleles (sickle cell, G6PD, O-blood group), but ambiguous or variable evidence even for some of these, and no statistical evidence for many other putative causal, or protective variants.  Further, they found that some variants had different effects in males and females, and one SNP, in the CD40LG gene, previously found to be associated with severe malaria, was associated with reduced risk in The Gambia, but significantly increased risk in Kenya.  Whether this is just statistical variation or indicators of other aspects of these local-area genomes isn't clear.

The evidence in the positive instances is persuasive, even if just statistical, but the conflicting results and the surprising lack of findings for so many is curious as well as discouraging.  How can it be that so long on, we still basically don't even know if a genetic variant is protective or not, other than the most classical ones? This shows how very challenging even 'simple' causation can be.

This raises the basic evolutionary issue in a different way. Darwin was convinced that adaptive evolution was very slow.  One major reason was that rapid changes of species or adaptations were rarely observed (still true), and if they occurred they could be interpreted as creationist rather than natural events.  Adaptive evolution under human direction, as in agricultural breeding, clearly brings about easily measured change.  But some forms of natural selection could be quite strong.  Adaptive coloration is one, but malaria should be another because it is so common and strong a negative effect on health.  So basic evolutionary arguments ought, it was long hoped, demonstrate that, in this instance, balancing selection was a correct explanation of at least these polymorphisms.

In past work, one hemoglobin variant (called hemoglobin E) has apparently been sweeping across southeast Asia because there was no down side to being an EE homozygote, and it protected against malaria.  But generally, the actual selective effect has been very hard to prove.  The new study shows this in a sobering way.  Is the story right?  Have prior speculations about protective mutations been too superficially offered, and incorrect?  Is the selective effect so small even in relation to malaria, that we can't see it even with samples large enough that 'nature' could have made a detectable selective difference?  Or, if so gradual in a Darwinian sense, do these other mutations really make an evolutionary difference?

Several relevant points are, first, that this study only looked at one form of malaria (P. falciparum), and second, that the different putative protective genes are involved in different physiological pathways.  And, as even the authors note, current patterns of disease, when antimalarial drugs are widely used, may not reflect patterns in the past, and thus it may not be possible to conclude that P. falciparum was the selective force these results suggest it may have been, plausible though that seems to be.  These points suggest that even here, complexity and subtlety are involved.

Beyond evolutionary theory
More sobering than the reality of detecting evolutionary or even genuine physiological differences among these various genotypes, is the further fact that even for these major and rather clear causal sites, there is still basically no progress in effective gene-based therapy.  After all, the target cells are in blood (generally, red cells), among the most easily accessible of all tissues.  Given the unrestrained promises repeatedly being made by the genomewide-do-everything industry, this is (or should be) a very sobering thought.  Our technological tools should, one might expect, have been able to solve such comparatively clear-cut problems.

To us, this 'failure' indicates the subtlety of genome physiology.  Given the hundreds of putatively causal single-gene findings by GWAS and other means, where the evidence has seemed strong, we should be showing that genomic data are, after all the expense and effort, really worth gathering.  We should be making a definitive, and one might say systematic, march toward elimination of these genetic threats, perhaps the way vaccines have done against many infectious diseases.  If we could actually do that, and speak of cures and prevention rather than just risk-estimation of countless minor factors, then nobody would disagree that further genomic big-science efforts were worth the investment.

Meanwhile, more than 70 years on, the largely failed effort to use that knowledge directly to rid our species of a disease that has been estimated to have killed more human beings than any other single cause, shows how far we have to go--and how important new sorts of thinking could potentially be to the effort.

And, into the bargain, perhaps we're learning a lot about how adaptive evolution works, reinforcing Darwin's ideas about its slowness, about multiple alternative or interactive pathways, and more.

Thursday, September 18, 2014

Malaria control now may not foretell the future

There are hailstorms, landslides, droughts, malaria and...the State. These are inescapable evils: such there always have been and there always will be.
                     Carlo Levi, Christ Stopped at Eboli: The Story of a Year, 1945
Malaria was once endemic in southern Europe, the UK, and the Americas.  It was in Greece at least 4000 years ago, and reached the Americas with or shortly after Columbus, eventually becoming an 'inescapable evil' when the slave trade was at its height.  With mosquito control due to DDT, cleaning up of standing water and other measures, the disease was essentially eliminated in the US and Canada and some parts of South America by 1950.  But the factors that maintain malaria in a population are complex, and it's possible that with climate change, global transfer of goods and increasing immigration from endemic areas, this, and other mosquito-borne diseases could return.

A recent episode of the BBC Radio 4 program, Costing the Earth, discussed the increasing spread of a number of mosquito species in the UK and throughout Europe.  In particular, the Asian tiger mosquito (Aedes albopictus), a voracious biter, has been spreading north from the Mediterranean for several decades.  It doesn't carry malaria, but it is a vector for other significant diseases including Yellow fever, Chikungunya, and nematodes that cause filariasis.  

Asian tiger mosquito; Wikipedia
The Costing the Earth episode pointed out that the mosquito is spreading for multiple reasons, perhaps a perfect storm of causation: temperatures are warming, sustained drought in the UK has meant that more and more people are collecting rain in buckets, to use in watering their gardens, and these standing pots of water have turned out to be a great reservoir for mosquito breeding, there is sustained wetland restoration happening in the country, tires shipped into the UK are also frequently full of stagnant water and thus mosquitoes and a number of species are entering the country via this route.  And so on.  But, mosquitoes that carry and transmit malaria still live in areas where malaria is no longer endemic, including the UK and the US.  So, it's not the absence of the vector that explains the absence of disease.

The dynamics of epidemics are well-understood, in mathematical, ecological and cultural detail (Aeon magazine has just published an excellent and accessible description of the mathematics of epidemics).  In the case of malaria, generally speaking, to maintain the disease in a population the population must be over a given size, there must be a reservoir of infected individuals for the mosquitoes to feed on, there must be a large enough mosquito population to transmit the disease to enough susceptible individuals, the fatality rate can't be so high that the parasite is quickly eliminated by death, environmental conditions must be favorable to the vector, and so on.  And, cultural factors must be favorable as well, so that, e.g., mosquitoes can find people to feed on or to infect at the right time of day or night.  That is, there are multiple factors required to maintain disease in a population, and often the infection can be halted by interfering with any one of them.

So, eliminating the vector, mosquitoes that carry the malarial parasite, is one approach to eliminating malaria, and as anything that breaks the chain of infection, vector control can successfully control the disease.  But, it's not required.  Reducing the prevalence of the disease to a level at which the host/vector ratio is no longer sufficient to transmit the disease widely, as was done in the US and Europe in the 1940's, is another way.  So, we in non-endemic areas of the world live with, and are bitten by potential vectors with no fear of infection with malaria, though now West Nile virus and Chikungunya are another story.  Indeed, this map shows the distribution of vectors or potential vectors around the globe.

            Global Distribution of Dominant or Potentially Important Malaria Vectors

From Kiszewksi et al., 2004. American Journal of Tropical Medicine and Hygiene 70(5):486-498, via the CDC.
Thus, where malaria has been eliminated, continued control depends on there being not enough infected individuals to sustain the infection.  Of course, this could change.  Southern Europe may be seeing the re-introduction of malaria, for example -- the disease has been spreading in Greece now for the first time in four decades.  In this case it can be blamed on the economic crisis and austerity because the government has not been able to pay for mosquito spraying, but the spread of malaria can't be blamed on mosquitoes alone; they've got to have an increased number of infected people to feed on as well. And it's not just malaria -- other heretofore neglected, unexpected, tropical diseases are reaching the shores of the US, and Europe, Chikungunya being one example.

We live in a dynamic, changing, interconnected world.  Malaria rates seem to have been declining in Africa and Asia, and research into better prevention and control is ongoing, and researchers can claim many successes.  But, like the proverbial fluttering of the butterfly wing that unpredictably causes climatic chaos far away, if innocuous acts like saving rain water in the UK can have widespread and unpredicted effects like increasing the spread of previously unknown mosquitoes, and thus potentially disease, it's hard to reliably predict that malaria will remain controlled in currently non-endemic areas.  This is not to be alarmist, but simply to point out that it's a bit hubristic to believe we can predict anything so complex, particularly when it requires predicting future environments.  We've said the same many times before about predicting complex disease from genes.

Carlo Levi (1902 - 1975) was an Italian painter, writer and physician.  Because of his political activism during the fascist era, he was exiled to a small southern town in Lucania, where he spent several years painting, writing and attending to the medical needs of the inhabitants there.  He wrote about this time in his book, Christ Stopped at Eboli, published in 1945.  It's a fascinating story; political, ethnographic, scientific (or quasi so).  Malaria was a fact of life in southern Italy at the time,  and Levi mentions it often in the book.  Including in this passage:
In this region malaria is a scourge of truly alarming proportions; it spares no one and when it is not properly cared for it can last a lifetime.  Productive capacity is lowered, the race is weakened, the savings of the poor are devoured; the result is a poverty so dismal and abject that it amounts to slavery without hope of emancipation.  Malaria arises from the impoverishment of the deforested clayey land, from neglected water, and inefficient tilling of the soil; in its turn it generates in a vicious circle the poverty of the peasants.  Public works on a large scale are necessary to uproot it.  The four main rivers of Lucania ... besides a host of lesser streams, should be dammed up; trees should be planted on the mountainsides; good doctors, hospitals, visiting nurses, medicines, and preventive measures should be made available to all.  Even improvements on a limited scale would have some effect...  But a general apathy prevails and the peasants continue to sicken and die.  
Levi may not have entirely understood the cause of malaria, but he clearly understood the vicious cycle of malaria and poverty, which he witnessed every day, all around him in exile.  As Dan Parker has written here on MT numerous times, economic development itself may be one of the best preventives we know.  But it may not always be enough.  It doesn't much matter which link in the chain of infection is broken; once repaired, we may have to figure out new ways to break the chain again.

Tuesday, July 15, 2014

More on IRBs and restraint on science

Stories over the last couple of days lead us to interrupt our series on natural selection with this brief post on research and ethical conundrums. It's a continuation of a couple of posts from last week (here and here) about IRBs (ethical review committees), bioethics and the idea of societal restraints on what scientists do or are permitted to be funded to do.

Nobody likes restraint, but science is supported by the public and science also has important public implications.  Nothing human is perfect or without potential down sides, including risks.  If society expects to benefit from new knowledge, it will have to pay for things that go nowhere and will also have to assume some risk.  The problem is how to assess work that shouldn't really be done, or paid for, and how to assess risk.
Our posts last week were about the indomitable scientist whose controversial work on engineering viruses--gain-of-function experiments--to make them dangerous went on despite disagreement about the public health consequences of the work.  Is it more important to protect public health by exploring the viruses in greater detail and thus enable the manufacture of better vaccines, or to do absolutely everything possible to prevent the public health disaster that could ensue if the viruses were to escape the lab?  That is, not make the organisms in the first place. 

Again, scientists are basically no more or less honorable than others in our society, and our society isn't exactly famous for its collective unity.  To the contrary, in a selfish society like ours, and when scientists have an idea and there may be money to be made (commercially or in grant funds), or potentially great public benefit, they are going to do what they can think up to get around rules that might stymie the objects of their desires.  That may include shading on honesty or not being as clear or forthcoming, or obfuscating.  Whatever works.  We're great at that--as can be seen in research papers (often, buried in the massive 'Supplemental' material!).  If you think that's not how things work, what planet do you live on?

But by coincidence, just since our posts about IRBs, infectious disease and science ethics, several significant and relevant events have come to light.  Six vials of smallpox virus were found buried in a lab freezer at the NIH in Washington, having been there since the 1954 (as reported by infectious disease writer Maryn McKenna in one of her fine series on this issue) when research into vaccines against the disease was underway, and before smallpox was eradicated; the last case on Earth was seen in 1978.  The vials were sent to the Centers for Disease Control in Atlanta (CDC), where it was discovered that 2 of them contained viable virus; McKenna reports that the samples will be destroyed after they've been thoroughly analyzed.

Officially, only 2 labs in the world still have smallpox samples; the CDC and a lab in Siberia.  The rationale for maintaining these stockpiles is that this would quickly enable whatever research would be necessary if the disease were to reappear -- presumably through biological warfare or terrorism rather than accidental release, but this does now put the latter possibility on the table.

But then in a widely reported story, the CDC found a 'lapsed culture' in infectious disease laboratories, the lax control potentially exposing workers to anthrax and shipping dangerous flu viruses.  The labs have been closed at least temporarily and external review requested.  No one hurt--this time.

Researchers do need to send potential dangerous samples to collaborators, and to work on them in their own labs (where, of course, employees do the actual work, not investigators).  The problem is that if or when an accident does occur, it could be of massively awful proportions.  The problem isn't new -- indeed, McKenna links to a 2007 piece in the USA Today reporting a long list of accidents in US labs handling "deadly germs".  Where is the line, and how do we draw it, to balance between the self- or selfish interest of scientists, the proper concern of government for public health measures, the potential for personal or corporate gain, the potentially major benefit to society, and the risks due to culpable avoidance of ethical standards (such as getting around the IRBs) or ordinary human fallibility?

Life involves risks as well as gains.  But unfortunately, risky research requires regulatory decisions about these issues by insiders, those with the knowledge but also conflict of interest, because it involves regulating themselves.  This is an area in which the public doesn't seem to have adequate means to be the guardians of our own interests.  No obvious solution comes to mind.

Monday, January 21, 2013

Disease driven poverty


In a few of my previous blog posts I’ve discussed the relationship between poverty and infectious disease.  Many of the most prevalent and severe infectious diseases in the world disproportionately affect the world’s poor.  Part of the reason is that the necessary resources aren’t available for tackling such diseases.  A lot of money is currently spent (wasted?) on designing biomedical ‘cures’ for diseases that persist in some places (usually economically poor places) while having already been eradicated in other places (usually economically rich).  It is my position that diseases such as malaria and tuberculosis remain major threats to some populations simply because of the way that financial resources are allocated in our extremely heterogeneous world.

But there is another angle to this story.

Not only does poverty lead to poor health, but poor health can also lead to poverty.  Quite frequently, that is, the arrows point both ways and the reality is a system in which there are “positive” feedback loops.  There is a growing literature on this type of system which is frequently referred to as a “poverty trap.”  Much of this literature has been in economics, where mathematical models have indicated that populations with infectious diseases are less able to ‘develop’ economically.

With economic development at the population level, e.g. with the growth of average income levels, we tend to see an increase in overall life expectancy at age 0.  Most likely this indicates a relationship between improved health and increased wealth.  However, most of the models that actually look at this relationship are either ecological (they are looking at the entire population and frequently assume homogeneity within the population) or at an individual level.  A few models have also looked at community or household levels.

One major problem with models of all types is that results can change when we change our unit of scale.  The effects of poverty on disease, for example, might be different if we look at a community level rather than a province/state level or even consider an entire nation to be a single population.  This is a problem known as the ecological fallacy (and is closely related to the modifiable areal unit problem) in which causal relationships at the population level don’t explain what is happening at, say, the individual level.  

Regardless of these problems and issues, there does appear to be a feedback loop between poverty and disease.

And this is an interesting thing from an anthropological view.  First off, poverty can mean different things to different people.  For example, to some, poverty means “not modern.”  Some indigenous groups actually choose to live in a traditional house rather than a more modern one.  In my opinion, “traditional” (or not modern) does not equal poverty, but it does get mistaken as poverty.  Poverty can also be a relative thing; something that becomes apparent when you don’t have as much stuff as the people with whom you are coming into contact.  Clearly this may lead to psychological and sociological issues, but it might also explain gradients in outcomes (relative health?)  Finally, there is a type of poverty that exists where people are simply unable to put food on the table.  While there can be some argument about the effects of modernization and relative poverty, I would suggest that this final type of poverty is unambiguous and its negative effects are less debatable.  

In poverty trap models we are frequently interested in investigating and understanding threshold levels under or above which equilibria are reached.  (There are quite a few relatively new papers out that are excellent references (see: Bonds, Keenan, Rohani, & Sachs, 2010; Plucinski, Ngonghala, Getz, & Bonds, 2013; Wood, n.d.)).  Perhaps it is easiest to consider at the unit of the household.

An already poor or marginally poor household in which the major breadwinner is afflicted by severe disease is plagued with multiple problems.  For example, aside from the risk of infection for other household members, if that person is afflicted by malaria or dengue fever, they may not be able to work for several weeks.  A house on the margin of poverty may then fall just enough behind in household money and/or food to fall into true poverty.  Households that are already poor may fall even further.

And an important aspect of this situation is that not only is the person who is actually infected met with further troubles; the entire house is also afflicted.  Furthermore, there tends to be heterogeneity in these effects even within households.  That is, poor households may see things such as greater infant mortality, and this effect may be exacerbated when there is a shortage of food or resources in the household.

In poverty trap models, there are usually equilibrium points in poverty levels that, once reached, are quite difficult to break.  From Bonds et al. (2010):

What may be most important in these debates is therefore not whether the effect of health on poverty is more significant than that of poverty on health, but whether the combined effect is powerful enough to generate self-perpetuating patterns of development or the persistence of poverty.  

Children who grow up in households with frequent food shortages may not have the same physical or cognitive abilities as others.  Their immune systems, already taxed by years of exposure to pathogens, may not be able to fight off diseases as well as their healthy counterparts.  Therefore, when they begin their own households, they are already behind in the nutrition, health, and economic game.  And once again, when adults in the new household fall ill and cannot put food on the table, the children will be disproportionately affected.  

This cyclical pattern, where disease leads to poverty and poverty can lead to disproportionate disease, provides a perfect storm in which there aren’t enough resources to keep from getting sick, where once sick you are likely to fall further into poverty, and once you fall further into poverty you are even further away from pulling yourself and your family out.  This leads to the maintenance of poverty and sickness across the generations.

And this story could perhaps get even more complicated when we consider some evolutionary implications.  For example, populations that have historically been afflicted with malaria also tend to have high proportions of blood and blood-related disorders that seem to protect against malaria.  Almost all of these disorders are harmful in some cases (for example, in homozygotes).  Therefore the evolutionary history of disease can lead to a situation where some individuals are actually plagued with sickness from the very beginning of life.  Paradoxically, under situations of heavy malaria burden, some people with these disorders will apparently be healthier than their non-affected counterparts.  I don’t know whether the side effects of these disorders are enough to lead to poverty traps on their own.

Finally, in an age when many scientists appear to be looking “for the gene for (fill in your favorite thing to study)”, poverty traps and households are an interesting thing to ponder.  Poverty and the apparent predisposition of household members toward succumbing to disease can look like a genetic effect.  If it runs in families, and certainly both poverty and sickness do, then it can look a whole lot like there is a genetic reason for it.  I think that poverty trap models are therefore a nice illustration of how we could arrive at the same phenotype (poverty and sickness) from purely socio-economic and ecological factors.  

REFERENCES:

Bonds, M. H., Keenan, D. C., Rohani, P., & Sachs, J. D. (2010). Poverty trap formed by the ecology of infectious diseases. Proceedings of the Royal Society B: Biological Sciences, 277(1685), 1185–92. doi:10.1098/rspb.2009.1778

Plucinski, M. M., Ngonghala, C. N., Getz, W. M., & Bonds, M. H. (2013). Clusters of poverty and disease emerge from feedbacks on an epidemiological network. Journal of The Royal Society Interface, 10(80), doi: 10.1098/rsif.2012.0656.

Wood, J. (in press). The Biodemography of Subsistence Farming: Population, Food and Family. Cambridge University Press.

Wednesday, November 28, 2012

The more we know, the more complex the web

In light of our recent post on helminth infection and its possible protective effects, Dan Parker, our resident infectious disease expert, alerted us to a new paper (Nov 15, open access) in Malaria Journal from a group in French Guyana about the effects of helminth infection on malaria infection and transmission. Titled "Helminth-infected patients with malaria: a low profile transmission hub?," the authors propose that concomitant malaria and helminth infection are a special problem.
Studies in humans have shown increased malaria incidence and prevalence, and a trend for a reduction of symptoms in patients with malaria. This suggests that such patients could possibly be less likely to seek treatment thus carrying malaria parasites and their gametocytes for longer durations, therefore, being a greater potential source of transmission. In addition, in humans, a study showed increased gametocyte carriage, and in an animal model of helminth-malaria co-infection, there was increased malaria transmission. These elements converge towards the hypothesis that patients co-infected with worms and malaria may represent a hub of malaria transmission.  

If this is true, because helminth infection and malaria overlap in much of the world, helminth control could be an important aspect of malarial control (though, does that then set people up for the chronic autoimmune diseases that seem to be associated with helminth control in the industrialized world?). The question of co-infection has not been ignored in the last decade or so, the authors write, but the results have been somewhat confusing. Infection with hookworm, for example, has been associated with increased malarial infection while infection with Ascaris is associated with lower incidence of malaria and decreased severity. Mechanisms have been proposed, such as that anemia increases susceptibility, or that helminth infection modulates immune responses, and differing study designs may account for some of the discrepancy.

But, if co-infection really is a factor in increased transmission and higher prevalence of malaria, this shows yet again the insidious complexity of malarial control. The new 'longform' digital magazine, Aeon, recently posted an essay by David Barash, evolutionary biologist "and aspiring Buddhist" that, among other things, described a project to understand why some years trees were more infested with gypsy moths than others. Gypsy moths cause great damage to North Eastern forests of the US, but only periodically.

 The suspicion was that gypsy moth periodicity was somehow connected with acorn crops, which vary greatly from year to year. High crop years were associated with low gypsy moth infestations, and vice versa. High crop years, as it turns out, are also associated with high white-footed deer mouse populations, too, as they love acorns. And they also love gypsy moth larvae, and feast on both.

But, white-tailed deer also love acorns, and they carry deer ticks, often infested with Lyme disease.
What are the practical implications? Foresters might be tempted to try to distribute additional acorns, inhibiting gypsy moth outbreaks in order to improve lumber yields. But this might bring about Lyme disease epidemics: more mice mean fewer gypsy moths, but also more ticks. Alternatively, public health officials who want to reduce Lyme disease might look into various ways of chemically suppressing mast production, which might in turn bring about gypsy moth infestations. Finally, it’s possible that Lyme disease outbreaks might be correlated, oddly enough, with how many acorns are produced that year by the forest.
The interconnected, ecological nature of life is, in part, what makes controlling deadly diseases like malaria, or debilitating helminth infections, so difficult. Each tweak has potential unintended consequences, to some degree because we don't really understand the whole web in the first place. Which only means we need to get better at seeing the whole.

Thursday, August 16, 2012

Start taking daily aspirin? Buy stock in Bayer?

An aspirin a day...
Last week we blogged about the possibility that many chronic diseases have an infectious origin. Cancers, heart disease, diabetes, asthma and so on rather than having a genetic cause, as the unlimited funding stream supporting the hunt for genes 'for' these diseases suggests, might be infectious instead.  It wouldn't be the first time that an unexpected infectious origin was found for a common disease -- stomach ulcers were thought to be due to stress for decades, and the suggestion that they might instead have a bacterial etiology was laughed out of court.  Until it was conclusively demonstrated to be the case.

Several studies now have suggested that aspirin taken daily in low doses might protect against some of the most common cancers, or prevent its recurrence, including a study just published in JNCI, the Journal of the National Cancer Institute, described in The Guardian here. Researchers pooled the results of a variety of clinical trials of aspirin as a preventive for vascular events -- stroke and heart attack, and found a significant reduction in cancer mortality.  The relative risk  in this sample of 100,000 people for those taking a daily low dose of aspirin for up to 11 years was 16% lower than in those not taking aspirin.  This was a smaller effect than that of previous studies -- e.g., a paper in The Lancet in March, one in a series of reports by the same author, reported that cancer mortality among people taking aspirin for at least 3 years was reduced by a quarter.

The latest results are still significant, but the benefit isn't nearly as clear-cut as earlier reports.  An editorial accompanying the paper in JNCI discusses the possible reasons for the differing results and concludes that the latest estimates are probably conservative.  How this will translate into clinical practice is yet to be determined.  There is some risk to a daily dose of aspirin, even if it's a low dose, because it is associated with internal bleeding.  So, as long as the size of the effect on cancer mortality is still uncertain doctors probably won't be recommending we all go on aspirin indefinitely. 

But how?
If it is true, though, what's the mechanism?  Aspirin is an NSAID, a non-steroidal anti-inflammatory drug, and its two major effects are to reduce inflammation and to inhibit blood clotting.  Some have suggested that platelets (blood clotting factors) are associated with cancer, but we explore the inflammation angle here instead because that lead seems more solid.  If tumors are infectious in origin, reducing inflammation could conceivably reduce the tumor.  A report in the May Current Biology, by Yi Feng et al., does suggest a link between cancer and inflammation, but the inflammation appears to be intrinsic to the tumor itself rather than due to an external infectious cause. 

An association between the COX2-PGE2 pathway and cancer progression is well-established (COX2 is a gene that regulates one of the prostaglandins, a hormonelike molecule involved in a diverse set of physiological processes such as uterine contraction and regulation of body temperature). COX2 is also associated with inflammation and pain, which is why so many pain relievers, including aspirin, are COX2 inhibitors.  It is known that COX-2 is expressed in the initial stages of tumorgenesis by malignant epithelial cells as well as other associated cells including macrophages, a component of the immune system.

Previous work by Feng et al. showed that innate immune cells were involved in the earliest stages of tumor proliferation.  They now have shown that PGE2 is the signal that is responsible for this.  They further show that blocking PGE2 synthesis by inhibiting COX2 expression slows tumor expansion, and suggest that this may be how aspirin, as a COX2 inhibitor, functions to slow tumor growth. 
We have provided evidence here that a trophic inflammatory response is important for a transformed cell to grow at its inception and that PGE2 produced by innate immune cells via the COX-2 pathway is a key trophic factor for optimal growth of transformed cells at the earliest stages of tumor progression. Moreover, this trophic inflammatory response can be suppressed by the inhibition of PGE2 production via COX-2 inhibitors, which might explain why use of non-steroidal anti-inflammatory drugs (NSAIDs) can reduce cancer incidence.
If further work confirms that aspirin inhibits tumor growth, and that the mechanism is as proposed by Feng and colleagues, this precludes the usual idea about cancer and inflammatory response.  Rather than infectious agents such as viruses or bacteria, the cells that initiate cancer in the first place are themselves inflammatory.

If that is the case, then cancer cells should show some mutations in inflammatory-related genes, that are not found in surrounding normal cells in the same person.  That would indicate that the evolution of a particular lineage of the person's cells included such mutation.  It allowed the cells to proliferate, eventually to the detriment of the person.

A kind of selection would prevent these variants from being in the germ line, because the embryo would develop misbehaving cells, and would die before ever being born.   This is not 'natural' selection of the usual Darwinian kind, which is about competition.  Instead, in the 'Mermaid's Tale' flavor, it is a failure of cooperation among developing cells within an individual.  But the effect is similar: it removes harmful variation.

Of course, this is a serendipitous finding if it holds up, because we did not evolve eating aspirin (that is, the same compound, in plants).  In the past, cancer got who cancer got.  Now, we may be able to counter-act this harmful somatic (body cell) evolution.

Thursday, August 9, 2012

The end of infectious disease?

When I was a graduate student at a School of Public Health in the late '70s there was, I believe, one remaining professor in the field of infectious disease, and he was on the verge of retirement.  His expertise was in tuberculosis, but since TB had been conquered -- well, as had all infectious diseases, at least in the US -- the school was waiting for him to leave so they could put more resources into the truly important diseases of the late 20th century; cancers, heart disease, diabetes.  These were caused environmentally rather than microbially.

This was still a few years before the first HIV/AIDS cases, and a while before resistance to antibiotics began to be widespread.  So perhaps it was understandable that Public Health rather arrogantly lumbered toward the end of the century with infectious diseases relegated to the back burner.

This was more than just a change in the names on faculty doors.  Infectious diseases have point causation: a single place and time of infection, and the one or few bugs that get in you and with high probability proliferate to produce disease.  Environmental epidemiology was about multifactorial, statistical causation, by lifestyle exposures, of which each only acts probabilistically in proportion to the amount and duration of exposure.  In a way, multivariate statisticians and computer analysis took the place of field epidemiology and laboratory research -- a pattern that Louis Pasteur had instigated in France in the 1800s, and so a profound change in expertise, outlook, and training of epidemiologists.

Then AIDS struck with a vengeance and brought TB along with it, broadsiding the medical and public health systems.  Initially the gay community in the US was particularly hard hit, but after Public Health/safe sex measures got that under control, the epidemic became essentially contained within the poor, intravenous drug using community in the US, and ignored by the rest of us.  So, still, infectious disease was not a problem.

Around about 1990, Ken contracted whooping cough, and so did our 8-year old daughter.  This is a serious disease, killing millions before the vaccine was introduced.  It's especially hard on infants.  Not one of five doctors in town -- pediatricians, GPs and an ENT -- recognized it for what it was.  One nurse told Ken that he couldn't have whooping cough because it had been eradicated.  A GP told him that he might have whooping cough, but he couldn't diagnose it because he'd never seen it.

My father, a pediatrician, diagnosed Ken when hearing him coughing in the background during a phone call I had with him.  He'd been vaccinated as a child, but immunity fades.  Our daughter was susceptible because she only was given the first of the 3 recommended pertussis vaccinations as an infant after the one she did get made her sick, after which the doctor said whooping cough wasn't a risk and recommended she not have the rest of the series.

Ok, so pertussis hit our family decades ago, when whooping cough just wasn't on anyone's radar because, we thought, infectious diseases were under control.  This year, though, pertussis epidemics have been declared in several states in the US, where they're seeing the highest number of cases in decades (e.g., Washington State).  It's disconcerting to see that much of the information on pertussis on the CDC webpage about the disease was last updated in 2010, though there is this map of increasing incidence in the last year.  Is this disease in fact on a whole lot more people's radar now than it was in 1990?


It was a BBC radio program that got me thinking about the disconnect between infectious disease reality and our perceptions.  The July 31 "File on 4" was a discussion of the skyrocketing incidence of TB in the UK, and how poorly the system is prepared to prevent or detect this serious communicable disease.  The program highlighted the cases of two young women with TB who were undiagnosed for far too long.  One died still undiagnosed and the other lost a lung and now her quality of life because their GPs didn't even consider TB as a diagnosis.

Prevalence in the UK has risen dramatically, largely but not entirely in communities with recent immigrants from Sub-Saharan Africa and South Asia, where TB prevalence is high.  Immigration services are not equipped to screen every traveler from high-risk areas for this disease, nor is the National Health Service.  But a physician not even thinking to consider TB is as much an impediment to its control as the lack of screening services.

And, it seems that when screening is considered, it's for active disease via chest x-rays, but 100 cases in immigrants were caught on x-ray last year, while an estimated 10,000 latent cases went undetected, and it's latent cases that are the real threat.  And, many of these are resistant to all known drugs used to treat the disease.

So, infectious diseases are again on the rise.  Vaccine deniers are the subject of much concern, but they're just a small part of the problem.  They essentially take advantage of the herd immunity provided them by the rest of us who do vaccinate our children, even if they may be responsible for small local outbreaks of various childhood diseases.  The steady march of evolving bacteria, parasites, and viruses that we can only react to, not predict is a much bigger problem, as is the continuing spread of resistance to whatever antibiotics we care to throw at the bugs. The lingering expectation that we've still got infectious diseases under control -- indeed, HIV is now a controllable chronic disease -- is another impediment.  Whooping cough has been eradicated, right?  And of course the ease of global travel facilitates the spread of infectious diseases.

But there's another thing that we don't yet know enough about, and that is how much the chronic supposedly environmental diseases we've spent so many hundreds of millions of dollars trying to parse genetically actually are due to some infectious component.  Genome-wide association studies (GWAS) have consistently found two things -- 1) multiple genes with very small effect and 2) many implicated genes associated with immune or inflammatory response.  And this for a wide variety of diseases.  So, it's possible that not only have we let classically infectious diseases creep back up on us with our eyes wide open, but that we've been treating other diseases as genetic when they are in fact infectious.  One author in particular has been trying to refocus attention on infectious causes of 'environmental' disease: Paul Ewald at the University of Indiana.  Others will be joining the chorus.

Infectious diseases are likely to have the last laugh.

Update: A discriminating reader writes to point out that Paul Ewald is at the University of Louisville, not Indiana.  

Friday, June 17, 2011

Infectious diseases in our time

As regular readers know, we usually very much enjoy the BBC Radio 4 program, In Our Time.  We were quite looking forward to last week's show on the origins of infectious disease, as it promised to touch on a number of our interests, but we were sorely disappointed.

It should have been good, and indeed some of it was quite informative in a very basic way -- appropriately, for a show for a general audience.  The guests were geneticist Steve Jones, professor of infectious disease epidemiology Roy Anderson and professor of microbial genomics Mark Pallen.  Presenter Melvin Bragg doesn't know this field, but he had some good questions about such things as when infectious diseases first began to affect humans, where they came from and indeed still come from.

They begin with the history of the bubonic plague, and Steve Jones spoke about its origins and natural history.  He said that the growth of population led to the spread of disease, and often the rise of an epidemic coincides with change in proximity to an animal, such as the rat in the case of the plague.

As he has done before, Jones talked about three epochs of human history: the age of disaster, the 99% of human history in which most people were killed by tigers or cold; the age of disease, the rise of population from the beginning of agriculture 10,000 years ago, which brought the rise of epidemics; and the age of decay, at least in the western world, where we now die of old age rather than infection.

While he didn't talk about this in the current program, he has said previously that he believes that we were molded by selection during the first two epochs, but that natural selection will no longer be a force that molds us now that we mostly survive to reproduce and pass on our genes.

But what an odd thing to say, as infectious diseases are still a primary killer, especially of children in much of the world, and aren't going away anytime soon.  And, more and more diseases seem to have an infectious component, so it may indeed turn out to be much more influential now, even as we 'decay', than Jones suspects.

Further, even before large population sizes and agriculture, much of our species was probably exposed to continual varieties of parasites, infections in injuries, and the like.  We are immersed in all sorts of viruses and bacteria, even if the clearly infectious diseases, that we easily notice, have to do with large, dense populations and close association with large herds of domestic animals.

And of course new infections arise all the time, and indeed Roy Anderson believes that the coming century is going to see a huge increase in emerging diseases given global population size and the ease with which people globe trot and thus spread disease.  The idea that humans -- or any species until it goes extinct -- have stopped evolving is just wrong.  Yes, we adapt to changing environments to a great extent, but new alleles arise with every birth, and there will always be change in our species' genotypes.  What is new -- for the moment -- is the rate and nature of change.

The rate of change will be much lower than in most of our past, so long as population size is so large.  Likewise, the great amount of intercontinental mixing will slow down the rate at which specific genotypes can be screened by selection, because there will be so many more genotypes in the global mix.  Even mass deaths, by modern standards, will usually be trivial in relation to whole population sizes -- that is, won't make much of a population bottleneck that would purge variation.  Variation very specific to serious disease susceptibility could, of course, disappear fast, but positively adaptive genetic variants will be much slower to advance in frequency than in most of our past.

Medical care and other perks and protections of modern society (until such society collapses of its own excesses) will change the nature of selection, but we'll still evolve.  But where our evolution will be most interesting may be how the pathogens evolve and adapt to us, because they can evolve very fast, especially confronted with the strong selective effect of antibiotics and the like.

Bragg asked if it's possible to generalize about where most viruses come from.  Anderson said that homo sapiens are 1/2 million years old (though it's not clear where that figure came from), and that we acquired all our infectious agents from wild animals before we domesticated animals, and then acquired disease from livestock.  Usually infection traveled in one direction, animals to humans, though several examples of infection going the other way did come up during the program -- we gave TB to cattle, and leprosy to armadillos, for example. An interesting twist, since sometimes now these pathogens mutate and get transferred back to us!

Jones was asked about the effect of animals on epidemics.  He said, as Anderson did, that indeed most diseases come from animals, but he then said that in fact the most dangerous animals are our closest relatives -- which is another odd thing to say on the face of it, as he'd just told us that the bubonic plague, one of the biggest killers ever, came from fleas via rats, and we get malaria from mosquitoes. We get relatively few such diseases from primates, so whether pigs and chickens are our 'closest' relatives in this context isn't clear.  But it is clear that population structure and habitat are important.

Jones also said that only recently, at the beginning of the 20th century, has medicine stopped killing more people than it cured.  But this is meaningless, as the denominator, the number of people who access medicine and what they go for, has changed dramatically.  It's comparing apples to, to ugli fruit.  Without affordable health care, few would have gone to the doctor for a common cold in the 19th century, but only when they were already deathly ill.  And probably most afflictions people see their doctors for now are self-limiting anyway, or at least aren't fatal, so of course a much smaller fraction of the people who see doctors now die.  Which is not to say that medicine hasn't improved, because of course it has.  

It is not at all clear that in the first age of humanity disaster killed more people or shortened life more than parasites of various kinds, nor that, overall, we're not still in the age of infection.  Certainly we suffer the slings and arrows of aging these days, but this is less clear outside of the 'developed' world, and indeed some of these slings and arrows may be laced with pathogens.  Also, in evolutionary thinking one might argue that even with rampant infection still so widespread, there are vastly more people alive today than ever before.  So whatever the changes, from an evolutionary point of view they've been good for our species, no matter how many suffer from whatever causes.

Pallen ends the program by saying that after they finish recording he wanted to talk with Jones about which theory was more important in terms of our understanding of the world and how we affect it, evolutionary theory or the germ theory.  What he meant, we assume, was that understanding how germs infect and kill, and their behavior in populations has allowed us to control them in ways that evolutionary theory could never do.  But in fact much of our immune system evolves, along with parasites, in the bodies of infected people.  So it seems an odd kind of comparison.
Evolutionary theory works far better and more clearly for such rapid adaptive changes, in our parasites, than those that happen in ourselves.  But asking whether evolutionary theory or the germ theory is more important is like asking which is more important, brakes or drapery.  They are both important  in their own way.  And evolutionary theory is a framework for understanding life, not a prescription.

Tuesday, November 30, 2010

Is asthma 'catching'? Is everything? Who said we'd defeated infectious disease?

The incidence of childhood asthma skyrocketed through the 1980s and 1990s and no one knows why.  Environmental epidemiologists have attributed the cause to a wide variety of factors including breastfeeding, bottle feeding, absence of helminth infestation, dirt, excessive cleanliness, air quality (good or bad), presence of pets in the household in infancy, the absence of pets, the use of acetaminophen in infancy, and even Facebook -- note that many of these are directly contradictory.  A few studies early on found that kids who grow up on farms tend to be at lower risk of asthma, and this led to the "Hygiene Hypothesis" which posits essentially that an immune system without enough to do is an immune system that goes awry.


A trend in epidemiology in the last few decades, in direct response to the inability to definitively identify environmental causes of complex diseases such as asthma or heart disease or type 2 diabetes, has been to look inward instead, to look for genes 'for' these diseases.  This isn't surprising, given the promises made by the Human Genome Project, for example, that knowing the genome would allow us to explain the majority of disease.  And, in fairness, given the great successes of human genetics early on at finding single genes for rare largely pediatric diseases like cystic fibrosis or Tay Sachs, the idea that genes could explain other diseases (even most diseases) was highly appealing and seductive.

But this meant that diseases were geneticized that, in our opinion, should have been left to the environmental epidemiologists -- genes can't explain an epidemic that took off as fast as the asthma epidemic did because gene frequencies don't change nearly fast enough.  Even if you posit that those who are affected have a genetic susceptibility to whatever environmental factor is triggering the disease, still it's clear that something rapidly changed in the environment, and, for our money, research dollars should be going toward finding that rather than genes.  (Why epidemiology has such a hard time finding such factors is another story, but it's largely because the tools of the trade are best at finding risk factors with large effects, such as infectious agents.  Though, why that hasn't been true of asthma, which, given the nature of the spike in incidence, seems to have had a main effect cause, is perplexing.)

But, largely because of this failure, many genetic studies of asthma have been done in the last several decades, including large genomewide association studies (GWAS).  And, just as with other genetic studies of complex diseases, in what is a rather repetitive drumbeat for trait after trait, nothing major has been found to reliably explain this epidemic.  Sure, some genes have been reported, but they just don't explain enough to be the answer.  Now researchers still interested in the genetics of asthma are suggesting, as with other complex diseases, that there must be numerous interacting genes with small effect.  Which is much more likely than one or two causative genes, yes, but it doesn't answer the question of what caused the epidemic.

There have been many ideas about the environmental component, most of them having to do not with pathogens but with pollutants, a number of candidates being listed above.  But now Science reports in the 26 November issue that there may be a bacterial link with asthma.  Again, the 'more microbes is better' hypothesis:
As odd as this might sound, there's mounting evidence that bacteria matter. Babies born via cesarean section, who experience a more sterile entry into the world than those born vaginally, are more likely to get asthma. So are young children treated with many courses of antibiotics. Along with animal studies, these observations suggest that the balance of bacteria and other microbes help guide immune development—and that when the balance is disrupted, disease may follow.
But it's complex.
All of us play host to bacterial residents. But children who develop asthma, researchers are learning, are home to different bacteria—and sometimes a less diverse mix—than those who stay healthy. “It's really coming down to the bacterial community structure, who's there, and in what numbers, and where,” [University of Michigan immunologist] Huffnagle says. 
So far, the evidence linking asthma and bacteria are associations, not proof that an imbalance of bacteria causes the disease. The big question, says Martinez, is, “Do asthmatics have an immune system that makes them be colonized by different things? … Or is it because they were colonized by different things that caused them to have asthma?” 
Researchers are currently comparing the microbiome (the community of microbes that colonize an individual) of kids with asthma and kids without, kids on farms, and kids in cities, to try to answer this question.  This is another way to ask if it's genes or environment -- which came first, the microbes, or the host environment?  And, of course many kids born by C section don't get asthma, and many kids born vaginally do.  It's complex indeed.

Microbiome analysis has some merits, beyond being yet another genomic Golden Calf for research labs. But we can predict that it is yet again a hunt for needles in a needle-stack of complexity.  We're likely still to be left with the problem that as a complex phenotype, like all other complex phenotypes, asthma is hard to explain, and hard to define.  In fact, an editorial in The Lancet several years ago suggested that every case should be considered unique, causally, physiologically and in how it's treated.

It is interesting, however, that schools of public health  abandoned their infectious disease departments in the '70s, declaring effectively that we'd won that battle (cheered on,  naturally, by geneticists seeing themselves as the funding beneficiaries).  Now, not only are clearly infectious issues like HIV/AIDS, multiple antibiotic resistant TB, SARS, and various influenzas still plaguing us, along with resurgent malaria and other neglected tropical diseases.  But many GWAS 'hits' are landing in genes involved in the immune system.

Inflammatory bowel disease, Crohn's disease, macular degeneration, and even schizophrenia are in this category.  If these pan out (and the first ones seem clearly to have done so), it means that non-acute, sub-clinical infection of long duration may build into diseases that did not seem either contagious or infectious.  If that's so, and the message sinks in, then GWAS may have done a service.  And epidemiologists like the sometimes-fringy Paul Ewald who have been touting the role of infectious role in chronic disease will have been vindicated.

Monday, July 19, 2010

Gut check!


A new article in PLoS Pathogens by a collaborative group led by Michael Riehle at the University of Arizona shows some progress in a long-sought genetic approach to disease control. While the news is, as usual, far ahead of the reality, the approach is interesting and may hold real promise for eventually helping to control one of the scourges of humankind--malaria.

The path is indirect and complicated to explain--but clever. Basically humans, and insects like mosquitoes, use insulin-like signaling among cells for their development. Mosquitoes depend on this from their blood meal. Riehle and colleagues have engineered a mosquito that carries a genetic change that over-activates a molecule (called Akt) in the insulin gene cascade, in the mosquito's gut.

The investigators said that a homozygous transgenic mosquito--one with two copies of the over-expressed gene--is 100% resistant to infection by the parasite.

The mosquito's lifespan is shortened by the insulin-cascade modification, so that the parasite's necessary time spent in its gut is too short for the parasite to fully develop, hence it's not ready to survive in the bitten human's blood stream. Hence, no malaria!

The idea that people have had in mind is not new, but this is a new approach. It's to 'seed' malaria-affected areas with these genetically modified mosquitoes, so that they would replace the native mosquitoes. The latter would simply die out by being out-competed in a sped-up evolutionary sense. If that happens, the parasite would have no insect gut in which to hide. That's why there would be no malaria.

Unfortunately, the engineered mosquitoes have a shortened lifespan and would likely be quickly out-competed by the local mosquitoes. Thus, the investigators will have to try some other genetic modification to give them a competitive advantage over the native mosquitoes. So we're years away from this kind of miracle.

Insecticides and anti-malarial drugs have the expected problem that they lead to resistance in Nature. The race to control mosquitoes by poisoning them, or to kill the parasite in humans, faces this kind of evolutionary arms race problem. The investigators hope their genetic approach might be added to the weapons we have against malaria.

Of course, there is every reason to expect that the parasite or transgenic mosquitoes would also develop genetic changes that could lead to reconnecting the pathogenic life cycles. There are many kinds of mosquitoes that carry lots of different malaria parasites, each of them different and naturally variable. So Nature can be predicted to out-wit any single genetic strategy. However, if the approach can be 'automated' and sped up, technology could continue to develop new attacks as current ones become ineffective.

In a different approach, British investigators are attempting to develop transgenic strategies against Dengue fever, another major killer (A story can be heard on the July 16 Science in Action program on the BBC). Again the idea is to seed the wild mosquito population with flies that in this case carry a gene expressing a toxin. The gene is inherited but in the absence of an antidote (which is not present in the wild), the descendants will die. If the transgenic flies mate successfully enough, the local population will die out. And so will the disease.  And, in yet another transgenic strategy, researchers are developing a female mosquito that can't fly; they project that the release of these mosquitoes into the wild would reduce the mosquito population drastically within 6-9 months, and thus reduce the Dengue fever problem.

It's still early days, but these strategies have in common the idea of strong artificial selection targeting specific genetic pathways in pathogens. One can hope they'll work.

Thursday, March 11, 2010

More on bugs

We've written before about how it seems that genomewide association studies are finding more and more genes associated with the immune system. And that's for a wide spectrum of conditions, from schizophrenia to macular degeneration to inflammatory bowel disease, and now, Alzheimer's Disease, according to a story in the NYTimes. These genes still explain only a small fraction of risk, but it is certainly starting to look like a trend.

The new hypothesis [about Alzheimer's] got its start late one Friday evening in the summer of 2007 in a laboratory at Harvard Medical School. The lead researcher, Rudolph E. Tanzi, a neurology professor who is also director of the genetics and aging unit at Massachusetts General Hospital, said he had been looking at a list of genes that seemed to be associated with Alzheimer’s disease.
To his surprise, many looked just like genes associated with the so-called innate immune system, a set of proteins the body uses to fight infections. The system is particularly important in the brain, because antibodies cannot get through the blood-brain barrier, the membrane that protects the brain. When the brain is infected, it relies on the innate immune system to protect it.
And, when researchers exposed the protein that constitutes plaque in the brains of many Alzheimer's patients to microbes, it was a fairly efficient killer. While a good fraction of people with dementia are found not to have these plaques upon autopsy, and many people without dementia do have them, the possibility that the innate immune system might fight infection of the brain as well as kill brain cells seems to be real. But it's a complex trait, and like any other complex trait, may well turn out to have more than one cause, one of which may be an innate immune system doing its job too efficiently.

The innate immune system attacks common features of microbes. That's different from the 'adaptive' immune system, which generates a huge array of different antibody molecules by random rearrangement of chromosomal segments (see Mermaid's Tale for some facts about these different systems). Variation in the latter is generated during your life, and inherited variation is not thought to be very important (since the system generates millions of new antibody configurations during your life). Variation in the innate immune system is inherited and works directly, the way genes are usually thought to work: the protein coded by the genetic variant (allele) that you inherit does its job at finding and poking holes in bacteria (or doesn't, depending on its configuration).

Infectious disease can be a strong effect. Whether or not it is systematic and durable enough to relate to natural selection over many generations, it may be that variation in susceptibility can lead to substantially different risk of disease to persons exposed to a given kind of pathogen. If that's the case, then mapping studies -- like GWAS, comparing cases and controls to find parts of the genome that seem to be related to case status -- might be able to detect the stronger risk-effects of genetic variation related to infectious disease. At least, it seems that for a wide variety of diseases a substantial fraction of GWAS 'hits' involve immune or inflammatory genes.

This could be a misleading surmise on our part. The 'immune' system does all sorts of jobs related to molecular recognition, and may involve a larger fraction of the genome than has been thought, so that its involvement in a given disease may not reflect infection, but some other function. Since as we said above these mapping 'hits' only account for a fraction of the case-control contrast, infection can't be the only causal factor.

Secondly, some studies find immune system 'hits' in diseases expected to involve infection, but not for other diseases (like heart disease) that are not. So not everything need be infectious. On the other hand, even something like heart disease risk can in part be due to infection, and instances and mechanisms are known that do that.

So there are interesting things to be found. If infection does turn out to be important, and if we keep over-using antibiotics, we may face a much more serious threat from that direction than from all the claimed 'genetic' risk that so much money is being spent to find by GWAS, biobanks, and other means. If that is the case, hopefully the research effort can be pried from the genetic vested interests in time to address the real problem before it's too late.